Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4531719
Max Phase: Preclinical
Molecular Formula: C20H23N5O
Molecular Weight: 349.44
Molecule Type: Unknown
Associated Items:
ID: ALA4531719
Max Phase: Preclinical
Molecular Formula: C20H23N5O
Molecular Weight: 349.44
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCCc1cn(-c2ccc(NC(=O)Nc3ccccc3C)cc2)nn1
Standard InChI: InChI=1S/C20H23N5O/c1-3-4-8-17-14-25(24-23-17)18-12-10-16(11-13-18)21-20(26)22-19-9-6-5-7-15(19)2/h5-7,9-14H,3-4,8H2,1-2H3,(H2,21,22,26)
Standard InChI Key: LZPQWTRWEKFHPZ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 349.44 | Molecular Weight (Monoisotopic): 349.1903 | AlogP: 4.56 | #Rotatable Bonds: 6 |
Polar Surface Area: 71.84 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.83 | CX Basic pKa: 0.25 | CX LogP: 5.06 | CX LogD: 5.06 |
Aromatic Rings: 3 | Heavy Atoms: 26 | QED Weighted: 0.68 | Np Likeness Score: -2.20 |
1. Brai A, Martelli F, Riva V, Garbelli A, Fazi R, Zamperini C, Pollutri A, Falsitta L, Ronzini S, Maccari L, Maga G, Giannecchini S, Botta M.. (2019) DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection., 62 (5): [PMID:30721061] [10.1021/acs.jmedchem.8b01403] |
2. Brai A, Boccuto A, Monti M, Marchi S, Vicenti I, Saladini F, Trivisani CI, Pollutri A, Trombetta CM, Montomoli E, Riva V, Garbelli A, Nola EM, Zazzi M, Maga G, Dreassi E, Botta M.. (2020) Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor., 11 (5): [PMID:32435411] [10.1021/acsmedchemlett.9b00681] |
3. Brai A,Riva V,Saladini F,Zamperini C,Trivisani CI,Garbelli A,Pennisi C,Giannini A,Boccuto A,Bugli F,Martini M,Sanguinetti M,Zazzi M,Dreassi E,Botta M,Maga G. (2020) DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins., 200 [PMID:32446036] [10.1016/j.ejmech.2020.112319] |
4. Brai A, Trivisani CI, Poggialini F, Pasqualini C, Vagaggini C, Dreassi E.. (2022) DEAD-Box Helicase DDX3X as a Host Target against Emerging Viruses: New Insights for Medicinal Chemical Approaches., 65 (15.0): [PMID:35899912] [10.1021/acs.jmedchem.2c00755] |
Source(1):